<div>Each year, approximately 300,000 people worldwide are afflicted with Complex Regional Pain Syndrome (CRPS; also called Reflex Sympathetic Dystrophy or causalgia), a neuro-inflammatory disorder that occurs in response to physical trauma such as a severe sprain, bone fracture, crush injury or surgery. CRPS causes nerves to misfire, sending constant pain signals to the brain, even long after the original injury has healed. The resulting pain is chronic, intense, disabling, and disproportionate to the original injury. The level of pain is measured as one of the most severe on the McGill University Pain Scale. 
</div>
<div><br />
</div>
<div>CRPS is difficult to diagnose, and there is no known cure. It is life altering, and negatively impacts daily activities, relationships, work and school. Yet, it remains one of the most widely under-recognized and misdiagnosed chronic pain conditions. Although significant strides have been made to better understand CRPS, more research must be done to fight this devastating disease. 
</div>
<div><br />
</div>
<div>Since 2015, the <a href="https://www.crpsconsortium.org/" target="_blank" rel="noreferrer noopener">International Research Consortium for CRPS</a>  has made it our mission to find more effective diagnostic and treatment options. With almost 80 individual members and 40 participating research sites, our members are international leaders in CRPS research, experienced and noted rising stars alike.  By fostering collaboration and coordination between researchers on a global scale, together we can achieve more compelling and relevant research results. 
</div>
<div><br />
</div>
<div>Now, we need to take our efforts to the next level. 
</div>
<div><br />
</div>
<div>Specifically, we want to answer a primary question that may dramatically affect the development of treatment options: Do all patients experience the same signs and symptoms -- or does it vary by stage or group? Is CRPS a uniform phenomenon across individuals, or are there distinct subtypes and/or stages? In other words, why do treatments work for some, but not others? 
</div>
<div><br />
</div>
<div>In 2003, experts gathered in Budapest to make recommendations for CRPS protocols, the results of which were published as the “Budapest criteria”. Since then, the Budapest criteria has become the definitive standard by which clinicians diagnose and treat CRPS. The founders of our organization, R. Norman Harden and Stephen Bruehl, were instrumental in validating the criteria.
</div>
<div><br />
</div>
<div>When it was originally established, the Budapest criteria was purposefully broad in its recommendations, and not designed for specific sub-types, stages or groups. This “umbrella” approach proved to be a vast improvement in CRPS research – but there’s more work to be done. Further research is needed to identify subsets of the disease so that more effective interventions can be developed.
</div>
<div><br />
</div>
<div>That’s where your donation comes in.
</div>
<div><br />
</div>
<div>With your financial support, we can develop the methodology to identify clinically significant subsets of CRPS such as warm and cold CRPS; CRPS-Type I (without “major nerve damage”), CRPS-Type II (with “major nerve damage”); stage of remission; and others. It will also enable us to conduct the studies required to achieve statistically relevant results. 
</div>
<div><br />
</div>
<div>You can learn more about our efforts <a href="https://www.crpsconsortium.org/" target="_blank" rel="noreferrer noopener">on our website</a>, crpsconsortium.org. If you’d like to learn more about CRPS in patients, please visit our sponsor’s website, <a href="https://rsds.org/about-rsda/" target="_blank" rel="noreferrer noopener">Reflex Sympathetic Dystrophy Syndrome Association </a> (RSDSA).
</div>
<div><br />
</div>
<div>Thank you in advance.
</div>

Anonymous

Peter Moskovitz

Lane Bollella

Geraldine Jones

JIJUN XU

Troy Haslam

Lana Santoro

Lori Alper

Christopher Herndon

Lisa R.

phyllis stagg

Complex Regional Pain Syndrome Research

platform

Platform is iOS

Android

Adyen Google Pay Development Audience

$opt_dummy_attribute

English only

Deprecate Stripe Legacy

dyn_template_ids

Adyen V6 Bene Transfer & MyMoney Campaign Organizers - test01

Bene transfer V6 and AdyenV6MyMoney Campaign Organizers - production

OneTrust next-app audience

fundCountryCode

NextDoor Share Option Users

Fundraisers with Reactions feature capability

fundCurrencyCode

US + Non-charity COs Only

locale

fund country is US and user language is English

personId

comms-internal-person-ids

Enhanced Story Experience Users

Suggested Goal Experience Users

user language is English and fund country: US, AU, DK, FI, IE, NO, SE, CA, GB; 

Poster share - new funds eligible (newest 9/18)

Streaming widgets beta user

paymentProcessor

3DS payment method

user language is English and fundCountry: US, AU, DK, FI, IE, NO, SE, CA, GB; 

GoFundMe Employees

ipAddress

Mark Rieth IP Address

Version 9.2.0 and above

Fund is in English speaking country

desktop

Android v12.11.0 and above

Platform is Android

paymentMethodType

checkoutType

Payment method type group to be vaulted on success

admin pr kit prod

EUR Donation Upsell

Share Text generation Skip Fundraiser

(prod) new funds eligible for amp12 (UGC gallery)

fintrac_cad_idv_form_v2 audience

paymentProcessorAccountId

fallback mode accounts

proCampaignId

p2p legacy startfundraising page

AMP24 New Funds Only PROD (DO NOT MODIFY)

countryCode

charityId

UKCharities

Federated Search Internal Testing

route.pathname community

US Donation Upsell audience 

Auto Thanks Feature Audience

Supporter Comments Eligible Funds

International Only

fundId

braze fundraiser group 

Payment Identity Transfers ATO Risk Check (Targeted) - Production

Fundraiser Saved Payment Method Rate Limit Bypass (Production)

leaderboard-partner-id-audience-givepanel

Version 9.2.1 and above

AUD Donation Upsell audience

fundraiserCountryCode is US/EN

Active Fundraiser - Smart Default Cadence

DAF Internal

Vault on success card payment method

Platform is iOS v11.0.0 and above

Desktop users

Person ids

United States (US) users

allow yuno fundraisers for test

Mexico country code

Posters INTL

NPO Profile Opted-In

iOS at or above 12.4.0

non-US recurring donors

Canada Campaign Owner Group

Fundraiser Without Meta Link

Scheduler payment tester gorup

charityCommunityId

Charities allow to be claimed unclaimed (PRD)

Canada (CA) users

currencyCode

UC Tipping v20250115 International

pymk_production_xplr_fe_team

Android at or above 12.2.0

Profile photo entry point audience

smart goals (fundraiser/manage) on test01

Activity Tracking v1 Beta Testing

writePath

Stream Notification

start gfm intl allowed locales

Platform is iOS v11.2.0 and above

unclaimed charities

prod_ach_audience

AI Chatbot Audience

amp13 only new funds (prod) (anyword auto)

UC Flow Enabled (Prod)

Payment Identity Beneficiary Verification - Production

shared notification bell audience

Custom users

ach frontend audience

Android v11.0.0 and above

Users Receiving Payments Paused Notifications

smart goals test01

Manage Coach - US English Organizers Only + new funds only

Team EGG - IP Address list

Fundraiser Without Instagram Deep Link

Native 11.4.0 and above

UC Tipping v20250107

Users Receiving Braze KYC Validation Failed

Native 11.3.0 and above

Influencer - Prod

US fundraisers and US users

ai_title_page

anyword

openai

control

manual_entry

userEmail

template_id

userId

fundUrl

isCharityCo

email

appVersion

shouldBucketIntoExperiment

partnerId

donationCadence

isActiveFundraiser

isPartner

isMobile

npoProfileOptIn

fundIsLinkedWithMeta

hasSessionDonation

isCampaignOwner

fundHasInstagramDeepLink

Native 11.4.0 and higher

New funds eligible - Video Sharing (PROD)

GB Donation Upsell audience 

Auto Thanks V3 Rollout Audience

Thank you V3 testing whitelist

isRecurringFriendly

Is Recurring Friendly

Excluded funds - Video Sharing

Logged In Users

CH Donation Upsell audience

Android v10.6.0 and above

userCurrencyCode

Localized Currency

v11.5.0 and above

testAudience

pathname

Survicate

appVersion is at or above 12.8.0

Non-charity fund

isChallengeFundraiser

challenge-fundraisers

Payment Identity Launch Verification - Production

New funds eligible - Posters v2

CAD Donation Upsell Audience

Braze Email Tester

NPO Profile Opted-Out

iOS App Version

hasKnownDonors

PYMK has donors

iOS v12.3.0 and above

Complex Regional Pain Syndrome Research

Still $35,535 to go. Help us build momentum.